€10.80
0.46% yesterday
Xetra, Jun 27, 05:36 pm CET
ISIN
DE000A3CMGM5
Symbol
APPH
Index
Sector
Industry

Apontis Pharma Stock price

€10.80
-0.75 6.49% 1M
+0.75 7.46% 6M
+0.75 7.46% YTD
+2.20 25.58% 1Y
-0.20 1.82% 3Y
-7.95 42.40% 5Y
-7.95 42.40% 10Y
-7.95 42.40% 20Y
Xetra, Closing price Fri, Jun 27 2025
-0.05 0.46%
ISIN
DE000A3CMGM5
Symbol
APPH
Index
Sector
Industry

Key metrics

Basic
Market capitalization
€92.2m
Enterprise Value
€76.8m
Net debt
€-15.5m
Cash
€15.5m
Shares outstanding
8.3m
Valuation (TTM | estimate)
P/E
72.00 | 24.40
P/S
1.29 | 1.57
EV/Sales
1.07 | 1.31
EV/FCF
negative
P/B
2.90
Financial Health
Equity Ratio
69.90%
Return on Equity
2.43%
ROCE
4.51%
ROIC
5.93%
Debt/Equity
0.00
Financials (TTM | estimate)
Revenue
€71.6m | €58.8m
EBITDA
€5.2m | €7.2m
EBIT
€1.8m
Net Income
€1.3m | €3.7m
Free Cash Flow
€-5.9m
Growth (TTM | estimate)
Revenue
156.68% | 21.38%
EBITDA
147.91% | 106.91%
EBIT
114.50%
Net Income
113.47% | 392.00%
Free Cash Flow
62.99%
Margin (TTM | estimate)
Gross
57.57%
EBITDA
7.19% | 12.31%
EBIT
2.47%
Net
1.75% | 6.27%
Free Cash Flow
-8.19%
More
EPS
€0.15
FCF per Share
€-0.70
Short interest
-
Employees
177.00
Rev per Employee
€270.00k
Show more

Is Apontis Pharma a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Apontis Pharma Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Apontis Pharma forecast:

1x Buy
9%
2x Hold
18%
8x Sell
73%

Analyst Opinions

11 Analysts have issued a Apontis Pharma forecast:

Buy
9%
Hold
18%
Sell
73%

Financial data from Apontis Pharma

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
72 72
157% 157%
100%
- Direct Costs 30 30
194% 194%
42%
41 41
135% 135%
58%
- Selling and Administrative Expenses 21 21
5% 5%
29%
- Research and Development Expense - -
-
-
5.15 5.15
148% 148%
7%
- Depreciation and Amortization 3.38 3.38
135% 135%
5%
EBIT (Operating Income) EBIT 1.77 1.77
115% 115%
2%
Net Profit 1.25 1.25
113% 113%
2%

In millions EUR.

Don't miss a Thing! We will send you all news about Apontis Pharma directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Apontis Pharma Stock News

AD HOC NEWS
16 days ago
APONTIS PHARMA AG / DE000A3CMGM5
AD HOC NEWS
about one month ago
APONTIS PHARMA AG / DE000A3CMGM5
More Apontis Pharma News

Company Profile

APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. Its single pill products focus on cardiovascular diseases such as hypertension, hyperlipidemia, and secondary prevention. The company was founded on March 19, 2018 and is headquartered in Monheim am Rhein, Germany.

Head office Germany
CEO Bruno Wohlschlegel
Employees 177
Founded 2018
Website www.apontis-pharma.de

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today